MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for severe eczema in toddlers
Disease control Not yet recruitingThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New injection shows promise for tough eczema in early trial
Disease control Not yet recruitingThis Phase 2 study tests a new biologic drug called AK139 in 168 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. Participants will receive either AK139 or a placebo by injection. The study aims to see if AK139 can safely clear skin and …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New eczema pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests an experimental drug called CMS-D001 in 160 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. Participants will take one of three doses of the drug or a placebo daily for several weeks. The main goal is to see…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Dermavon Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill could ease severe eczema in major trial
Symptom relief Not yet recruitingThis phase 3 study tests an oral tablet called LW402 in 480 adults with moderate-to-severe atopic dermatitis (eczema). Participants will take either the drug or a placebo daily for 16 weeks. The goal is to see if LW402 can significantly improve eczema severity and skin clearance …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New eczema pill aims to calm angry skin
Symptom relief Not yet recruitingThis study tests an experimental capsule called QLS12010 in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo over 16 weeks. Participants must have had eczema for at least one year…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC